Eccles Suzanne A
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, McElwain Labs, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
IDrugs. 2010 Nov;13(11):768-71.
The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research developments in the field of metastasis and tumor microenvironment. This conference report highlights selected presentations on translation targets from a clinical perspective, antibody inhibitors of TGFβ for metastasis suppression, metastasis in bladder and lung cancer, c-ErbB2/HER2 expression in ductal carcinomas in situ and breast cancer, targeting Hsp90 chaperones in solid cancers, peritoneal carcinomas, and the discovery and exploitation of RANK ligands in bone metastasis. Investigational drugs discussed include the humanized antibody against TGFβ fresolimumab (GC-1008; Genzyme), the anti-VEGFR1 antibody icrucumab (IMC-18F1; ImClone Systems) and the novel Hsp90 inhibitor NVP-AUY-922 (AUY-922, VER-52296; Novartis).
在费城召开的转移与肿瘤微环境会议涵盖了转移和肿瘤微环境领域新研究进展等主题。本会议报告重点介绍了从临床角度出发的选定演讲内容，包括用于抑制转移的TGFβ抗体抑制剂、膀胱癌和肺癌中的转移、原位导管癌和乳腺癌中的c-ErbB2/HER2表达、实体癌中靶向Hsp90伴侣蛋白、腹膜癌以及骨转移中RANK配体的发现与应用。所讨论的研究药物包括抗TGFβ人源化抗体fresolimumab（GC-1008；健赞公司）、抗VEGFR1抗体icrucumab（IMC-18F1；英克隆系统公司）以及新型Hsp90抑制剂NVP-AUY-922（AUY-922，VER-52296；诺华公司）。
